Juan Maza-Solano , Carmen Palma-Martínez , Daniel Martín-Jiménez , Serafín Sánchez-Gómez , Ramón Moreno-Luna , Christian Calvo-Henriquez , Hugo Galera-Ruiz
{"title":"降压治疗对患有鼻息肉的慢性鼻炎患者生活质量的影响","authors":"Juan Maza-Solano , Carmen Palma-Martínez , Daniel Martín-Jiménez , Serafín Sánchez-Gómez , Ramón Moreno-Luna , Christian Calvo-Henriquez , Hugo Galera-Ruiz","doi":"10.1016/j.otorri.2023.08.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>Nasal polyposis (CRSwNP) shares type<!--> <!-->2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.</p></div><div><h3>Materials and methods</h3><p>Retrospective study of 43 patients with CRSwNP and AH with at least 1<!--> <!-->year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.</p></div><div><h3>Results</h3><p>The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1<!--> <!-->=<!--> <!-->27.9% and F2<!--> <!-->=<!--> <!-->6.97%). A significant reduction in polypoid size, SNOT22 (16.4<!--> <!-->±<!--> <!-->19.6 points), and VAS scales (<em>P</em> <!--><<!--> <!-->.05) was obtained.</p></div><div><h3>Conclusions</h3><p>Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence.</p></div>","PeriodicalId":7019,"journal":{"name":"Acta otorrinolaringologica espanola","volume":"75 3","pages":"Pages 155-161"},"PeriodicalIF":0.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efecto del tratamiento antihipertensivo en la calidad de vida de los pacientes con rinosinusitis crónica con pólipos nasales\",\"authors\":\"Juan Maza-Solano , Carmen Palma-Martínez , Daniel Martín-Jiménez , Serafín Sánchez-Gómez , Ramón Moreno-Luna , Christian Calvo-Henriquez , Hugo Galera-Ruiz\",\"doi\":\"10.1016/j.otorri.2023.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim</h3><p>Nasal polyposis (CRSwNP) shares type<!--> <!-->2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.</p></div><div><h3>Materials and methods</h3><p>Retrospective study of 43 patients with CRSwNP and AH with at least 1<!--> <!-->year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.</p></div><div><h3>Results</h3><p>The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1<!--> <!-->=<!--> <!-->27.9% and F2<!--> <!-->=<!--> <!-->6.97%). A significant reduction in polypoid size, SNOT22 (16.4<!--> <!-->±<!--> <!-->19.6 points), and VAS scales (<em>P</em> <!--><<!--> <!-->.05) was obtained.</p></div><div><h3>Conclusions</h3><p>Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence.</p></div>\",\"PeriodicalId\":7019,\"journal\":{\"name\":\"Acta otorrinolaringologica espanola\",\"volume\":\"75 3\",\"pages\":\"Pages 155-161\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta otorrinolaringologica espanola\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001651923001164\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001651923001164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Efecto del tratamiento antihipertensivo en la calidad de vida de los pacientes con rinosinusitis crónica con pólipos nasales
Aim
Nasal polyposis (CRSwNP) shares type 2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.
Materials and methods
Retrospective study of 43 patients with CRSwNP and AH with at least 1 year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.
Results
The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1 = 27.9% and F2 = 6.97%). A significant reduction in polypoid size, SNOT22 (16.4 ± 19.6 points), and VAS scales (P < .05) was obtained.
Conclusions
Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence.
期刊介绍：
Es la revista más importante en español dedicada a la especialidad. Ofrece progresos científicos y técnicos tanto a nivel de originales como de casos clínicos. Además, es la Publicación Oficial de la Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial y está presente en los más prestigiosos índices de referencia.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
